Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 1, 2013, Pages 119-128

  David, Diana ^a   Nair, S Asha ^a   Pillai, M Radhakrishna ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Carcinogenesis; HECT E3 ligase; Smurf1; Smurf2; Tumor suppressor

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CELL PROTEIN; HEAT SHOCK PROTEIN; HISTONE; INHIBITOR OF DIFFERENTIATION 1; KRUPPEL LIKE FACTOR; NEDD9 PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN HPEM 2; PROTEIN P16; PROTEIN P53; PROTEIN RNF20; RAP1 PROTEIN; RAP1B PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD UBIQUITIN REGULATORY FACTOR 1; SMAD UBIQUITIN REGULATORY FACTOR 2; TALIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CATALYSIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHROMATIN; DNA REPAIR; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; EPIGENETICS; GENOMIC INSTABILITY; HISTONE MODIFICATION; HUMAN; METASTASIS; MITOSIS SPINDLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84871028971     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.11.003     Document Type: Review

References (91)

1. Chen D., Ping Dou Q. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 2010, 11:459-470.
2. Bernassola F., Karin M., Ciechanover A., Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008, 14:10-21.
3. Hoeller D., Hecker C.M., Wagner S., Rogov V., Dötsch V., Dikic I. E3-independent monoubiquitination of ubiquitin-binding proteins. Mol. Cell 2007, 26:891-898.
4. Zhu H., Kavsak P., Abdollah S., Wrana J.L., Thomsen G.H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999, 400:687-693.
5. Lin X., Liang M., Feng X.H. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. J. Biol. Chem. 2000, 275:36818-36822.
6. Osmundson E.C., Ray D., Moore F.E., Gao Q., Thomsen G.H., Kiyokawa H. The HECT E3 ligase Smurf2 is required for Mad2-dependent spindle assembly checkpoint. J. Cell Biol. 2008, 183:267-277.
7. Wang H.R., Ogunjimi A.A., Zhang Y., Ozdamar B., Bose R., Wrana J.L. Degradation of RhoA by Smurf1 ubiquitin ligase. Methods Enzymol. 2006, 406:437-447.
8. Huang C. Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh. Migr. 2010, 4:10.
9. Zhang H., Cohen S.N. Smurf2 up-regulation activates telomere-dependent senescence. Genes Dev. 2004, 18:3028-3040.
10. Zhang H., Teng Y., Kong Y., Kowalski P.E., Cohen S.N. Suppression of human tumor cell proliferation by Smurf2-induced senescence. J. Cell. Physiol. 2008, 215:613-620.
11. Jin C., Yang Y., Anver M.R., Morris N., Wang X., Zhang Y.E. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res. 2009, 69:735.
12. Fukuchi M., Fukai Y., Masuda N., Miyazaki T., Nakajima M., Sohda M., Manda R., Tsukada K., Kato H., Kuwano H. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res. 2002, 62:7162.
13. Loukopoulos P., Shibata T., Katoh H., Kokubu A., Sakamoto M., Yamazaki K., Kosuge T., Kanai Y., Hosoda F., Imoto I. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 2007, 98:392-400.
14. Fukasawa H., Yamamoto T., Fujigaki Y., Misaki T., Ohashi N., Takayama T., Suzuki S., Mugiya S., Oda T., Uchida C. Reduction of transforming growth factor-β type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma. Int. J. Cancer 2010, 127:1517-1525.
15. Tan R., He W., Lin X., Kiss L.P., Liu Y. Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication. Am. J. Physiol. Renal Physiol. 2008, 294:F1076-F1083.
16. Tan R., Zhang J., Tan X., Zhang X., Yang J., Liu Y. Downregulation of SnoN expression in obstructive nephropathy is mediated by an enhanced ubiquitin-dependent degradation. J. Am. Soc. Nephrol. 2006, 17:2781-2791.
17. Blank M., Tang Y., Yamashita M., Burkett S.S., Cheng S.Y., Zhang Y.E. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat. Med. 2012, 18:227-234.
18. Chen C., Matesic L.E. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 2007, 26:587-604.
19. Chong P.A., Lin H., Wrana J.L., Forman-Kay J.D. An expanded WW domain recognition motif revealed by the interaction between Smad7 and the E3 ubiquitin ligase Smurf2. J. Biol. Chem. 2006, 281:17069-17075.
20. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., Wrana J.L. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol. Cell 2000, 6:1365-1375.
21. Chong P.A., Lin H., Wrana J.L., Forman-Kay J.D. Coupling of tandem Smad ubiquitination regulatory factor (Smurf) WW domains modulates target specificity. Proc. Natl. Acad. Sci. 2010, 107:18404-18409.
22. Tajima Y., Goto K., Yoshida M., Shinomiya K., Sekimoto T., Yoneda Y., Miyazono K., Imamura T. Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-β signaling by Smad7. J. Biol. Chem. 2003, 278:10716-10721.
23. Murakami K., Mathew R., Huang J., Farahani R., Peng H., Olson S.C., Etlinger J.D. Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension. Exp. Biol. Med. 2010, 235:805-813.
24. Lu K., Yin X., Weng T., Xi S., Li L., Xing G., Cheng X., Yang X., Zhang L., He F. Targeting WW domains linker of HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1. Nat. Cell Biol. 2008, 10:994-1002.
25. Cheng P., Lu H., Shelly M., Gao H., Poo M. Phosphorylation of E3 ligase Smurf1 switches its substrate preference in support of axon development. Neuron 2011, 69:231-243.
26. Ogunjimi A.A., Briant D.J., Pece-Barbara N., Le Roy C., Di Guglielmo G.M., Kavsak P., Rasmussen R.K., Seet B.T., Sicheri F., Wrana J.L. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol. Cell 2005, 19:297-308.
27. Kee Y., Huibregtse J.M. Regulation of catalytic activities of HECT ubiquitin ligases. Biochem. Biophys. Res. Commun. 2007, 354:329-333.
28. Wiesner S., Ogunjimi A.A., Wang H.R., Rotin D., Sicheri F., Wrana J.L., Forman-Kay J.D. Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. Cell 2007, 130:651-662.
29. Subramaniam V., Li H., Wong M., Kitching R., Attisano L., Wrana J., Zubovits J., Burger A., Seth A. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br. J. Cancer 2003, 89:1538-1544.
30. Nie J., Xie P., Liu L., Xing G., Chang Z., Yin Y., Tian C., He F., Zhang L. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. J. Biol. Chem. 2010, 285:22818.
31. Guo X., Wang X.F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 2008, 19:71-88.
32. Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. 2001, 98:974.
33. Ying S.X., Hussain Z.J., Zhang Y.E. Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation. J. Biol. Chem. 2003, 278:39029-39036.
34. Izzi L., Attisano L. Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation. Oncogene 2004, 23:2071-2078.
35. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J. Clin. Invest. 2004, 113:253-264.
36. Bonni S., Wang H.R., Causing C.G., Kavsak P., Stroschein S.L., Luo K., Wrana J.L. TGF-β induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat. Cell Biol. 2001, 3:587-595.
37. Nourry C., Maksumova L., Pang M., Liu X., Wang T. Direct interaction between Smad3, APC10, CDH1 and HEF1 in proteasomal degradation of HEF1. BMC Cell Biol. 2004, 5:20.
38. Morén A., Imamura T., Miyazono K., Heldin C.H., Moustakas A. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J. Biol. Chem. 2005, 280:22115-22123.
39. Ito I., Hanyu A., Wayama M., Goto N., Katsuno Y., Kawasaki S., Nakajima Y., Kajiro M., Komatsu Y., Fujimura A. Estrogen inhibits transforming growth factor β signaling by promoting Smad2/3 degradation. J. Biol. Chem. 2010, 285:14747.
40. Pray T.R., Parlati F., Huang J., Wong B.R., Payan D.G., Bennett M.K., Issakani S.D., Molineaux S., Demo S.D. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist. Updat. 2002, 5:249-258.
41. Nakayama K.I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006, 6:369-381.
42. Dadke D., Jarnik M., Pugacheva E.N., Singh M.K., Golemis E.A. Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle. Mol. Biol. Cell 2006, 17:1204-1217.
43. Michel L., Benezra R., Diaz-Rodriguez E. MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword. Cell Cycle 2004, 3:990.
44. Xie P., Tang Y., Shen S., Wang Y., Xing G., Yin Y., He F., Zhang L. Smurf1 ubiquitin ligase targets Kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells. Biochem. Biophys. Res. Commun. 2011, 407:254-259.
45. Du J.X., Hagos E.G., Nandan M.O., Bialkowska A.B., Yu B., Yang V.W. The E3 ubiquitin ligase SMAD ubiquitination regulatory factor 2 negatively regulates Krüppel-like factor 5 protein. J. Biol. Chem. 2011, 286:40354-40364.
46. Sotillo R., Hernando E., Díaz-Rodríguez E., Teruya-Feldstein J., Cordón-Cardo C., Lowe S.W., Benezra R. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007, 11:9-23.
47. Izumchenko E., Singh M.K., Plotnikova O.V., Tikhmyanova N., Little J.L., Serebriiskii I.G., Seo S., Kurokawa M., Egleston B.L., Klein-Szanto A. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009, 69:7198.
48. Kim M., Gans J.D., Nogueira C., Wang A., Paik J.H., Feng B., Brennan C., Hahn W.C., Cordon-Cardo C., Wagner S.N. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006, 125:1269-1281.
49. Wang H.R., Zhang Y., Ozdamar B., Ogunjimi A.A., Alexandrova E., Thomsen G.H., Wrana J.L. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Sci. STKE 2003, 302:1775.
50. Sun R., Chen X., Yang V.W. Intestinal-enriched Krüppel-like factor (Krüppel-like factor 5) is a positive regulator of cellular proliferation. J. Biol. Chem. 2001, 276:6897-6900.
51. Moore F.E., Osmundson E.C., Koblinski J., Pugacheva E., Golemis E.A., Ray D., Kiyokawa H. The WW-HECT protein Smurf2 interacts with the docking protein NEDD9/HEF1 for Aurora A activation. Cell Div. 2010, 5:22.
52. Conkright M.D., Wani M.A., Anderson K.P., Lingrel J.B. A gene encoding an intestinal-enriched member of the Krüppel-like factor family expressed in intestinal epithelial cells. Nucleic Acids Res. 1999, 27:1263-1270.
53. Swamynathan S.K. Krüppel-like factors: three fingers in control. Hum. Genom. 2010, 4:263-270.
54. Huang C., Rajfur Z., Yousefi N., Chen Z., Jacobson K., Ginsberg M.H. Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nat. Cell Biol. 2009, 11:624-630.
55. Schwamborn J.C., Müller M., Becker A.H.M., Püschel A.W. Ubiquitination of the GTPase Rap1B by the ubiquitin ligase Smurf2 is required for the establishment of neuronal polarity. EMBO J. 2007, 26:1410-1422.
56. Yamaguchi K., Ohara O., Ando A., Nagase T. Smurf1 directly targets hPEM-2, a GEF for Cdc42, via a novel combination of protein interaction modules in the ubiquitin-proteasome pathway. Biol. Chem. 2008, 389:405-413.
57. Yang Q., Chen S.P., Zhang X.P., Wang H., Zhu C., Lin H.Y. Smurf2 participates in human trophoblast cell invasion by inhibiting TGF-β Type I receptor. J. Histochem. Cytochem. 2009, 57:605.
58. Crose L.E.S., Hilder T.L., Sciaky N., Johnson G.L. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. J. Biol. Chem. 2009, 284:13301-13305.
59. Fukunaga E., Inoue Y., Komiya S., Horiguchi K., Goto K., Saitoh M., Miyazawa K., Koinuma D., Hanyu A., Imamura T. Smurf2 induces ubiquitin-dependent degradation of Smurf1 to prevent migration of breast cancer cells. J. Biol. Chem. 2008, 283:35660-35667.
60. Asanuma K., Yanagida-Asanuma E., Faul C., Tomino Y., Kim K., Mundel P. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat. Cell Biol. 2006, 8:485-491.
61. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15.
62. Nie J., Liu L., Wu M., Xing G., He S., Yin Y., Tian C., He F., Zhang L. HECT ubiquitin ligase Smurf1 targets the tumor suppressor ING2 for ubiquitination and degradation. FEBS Lett. 2010, 584:3005-3012.
63. Guo X., Shen S., Song S., He S., Cui Y., Xing G., Wang J., Yin Y., Fan L., He F. The E3 ligase Smurf1 regulates Wolfram syndrome protein stability at the endoplasmic reticulum. J. Biol. Chem. 2011, 286:18037.
64. Li H., Seth A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 2004, 23:1801-1808.
65. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
66. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004, 429:86-92.
67. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112:779-791.
68. Chen D., Kon N., Li M., Zhang W., Qin J., Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005, 121:1071-1083.
69. Esser C., Scheffner M., Höhfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 2005, 280:27443-27448.
70. Khalil A.A., Kabapy N.F., Deraz S.F., Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?. Biochim. Biophys. Acta, Rev. Cancer 2011, 1816:89-104.
71. Garrido C., Schmitt E., Candé C., Vahsen N., Parcellier A., Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003, 2:579.
72. Sun Y., Zhou M., Fu D., Xu B., Fang T., Ma Y., Chen J., Zhang J. Ubiquitination of heat shock protein 27 is mediated by its interaction with Smad ubiquitination regulatory factor 2 in A549 cells. Exp. Lung Res. 2011, 37:568-573.
73. Wrighton K.H., Lin X., Feng X.H. Critical regulation of TGFβ signaling by Hsp90. Proc. Natl. Acad. Sci. 2008, 105:9244.
74. Ishihara H., Takeda S., Tamura A., Takahashi R., Yamaguchi S., Takei D., Yamada T., Inoue H., Soga H., Katagiri H. Disruption of the WFS1 gene in mice causes progressive β-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum. Mol. Genet. 2004, 13:1159-1170.
75. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., Weinstein R.S., O'Brien C.A., Manolagas S.C., Jilka R.L. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. Sci. STKE 2003, 278:50259.
76. Han G., Li A.G., Liang Y.Y., Owens P., He W., Lu S., Yoshimatsu Y., Wang D., ten Dijke P., Lin X. Smad7-induced [beta]-catenin degradation alters epidermal appendage development. Dev. Cell 2006, 11:301-312.
77. Carpentier I., Coornaert B., Beyaert R. Smurf2 is a TRAF2 binding protein that triggers TNF-R2 ubiquitination and TNF-R2-induced JNK activation. Biochem. Biophys. Res. Commun. 2008, 374:752-757.
78. Li S., Lu K., Wang J., An L., Yang G., Chen H., Cui Y., Yin X., Xie P., Xing G. Ubiquitin ligase Smurf1 targets TRAF family proteins for ubiquitination and degradation. Mol. Cell. Biochem. 2010, 338:11-17.
79. Benezra R., Davis R.L., Lockshon D., Turner D.L., Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990, 61:49.
80. Iavarone A., Garg P., Lasorella A., Hsu J., Israel M.A. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 1994, 8:1270-1284.
81. Bond J., Jones C., Haughton M., DeMicco C., Kipling D., Wynford-Thomas D. Direct evidence from siRNA-directed. Exp. Cell Res. 2004, 292:151-156.
82. Brookes S., Rowe J., Gutierrez del Arroyo A., Bond J., Peters G. Contribution of p16INK4a to replicative senescence of human fibroblasts. Exp. Cell Res. 2004, 298:549-559.
83. Kong Y., Cui H., Zhang H. Smurf2-mediated ubiquitination and degradation of Id1 regulates p16 expression during senescence. Aging Cell 2011, 10:1038-1046.
84. Zhu B., Zheng Y., Pham A.D., Mandal S.S., Erdjument-Bromage H., Tempst P., Reinberg D. Monoubiquitination of human histone H2B: the factors involved and their roles in< i> HOX gene regulation. Mol. Cell 2005, 20:601-611.
85. Minsky N., Shema E., Field Y., Schuster M., Segal E., Oren M. Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat. Cell Biol. 2008, 10:483-488.
86. Moyal L., Lerenthal Y., Gana-Weisz M., Mass G., So S., Wang S.Y., Eppink B., Chung Y.M., Shalev G., Shema E. Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. Mol. Cell 2011, 41:529-542.
87. Nakamura K., Kato A., Kobayashi J., Yanagihara H., Sakamoto S., Oliveira D.V.N.P., Shimada M., Tauchi H., Suzuki H., Tashiro S. Regulation of homologous recombination by RNF20-dependent H2B ubiquitination. Mol. Cell 2011, 41:515-528.
88. Kwei K.A., Shain A.H., Bair R., Montgomery K., Karikari C.A., van de Rijn M., Hidalgo M., Maitra A., Bashyam M.D., Pollack J.R. SMURF1 amplification promotes invasiveness in pancreatic cancer. PLoS One 2011, 6:e23924.
89. Scheffner M., Staub O. HECT E3s and human disease. BMC Biochem. 2007, 8:S6.
90. Lakshmanan M., Bughani U., Duraisamy S., Diwan M., Dastidar S., Ray A. Molecular targeting of E3 ligases-a therapeutic approach for cancer. Expert Opin. Ther. Targets 2008, 12:855-870.
91. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006, 8:645.